Please note, this OEL/ADE monograph also applies to valproic acid (CAS RN 99-66-1) and divalproex sodium (CAS RN 76584-70-8). Valproate, which is a generic name applied to valproic acid and its salts and esters, is indicated for the treatment and management of seizure disorders, mania, and prophylactic treatment of migraine headaches. Valproate sodium injection is indicated as an intravenous (IV) alternative in patients for whom oral administration of valproate products is temporarily not feasible in the treatment of seizure disorders.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Valproate Sodium, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.